Solid Antiviral Dosage Forms for Hepatitis C Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, particularly those involving peginterferon-alpha and ribavirin, suffer from limited efficacy and significant side effects, necessitating the development of new drugs that can effectively treat HCV while overcoming challenges such as poor solubility, bioavailability, and pharmacokinetic profile variability of antiviral compounds like ABT-450, ABT-267, ritonavir, and dasabuvir.
Innovation Solution
Development of solid dosage forms comprising Compound 1 (ABT-450), Compound 2 (ABT-267), Compound 3 (ritonavir), and Compound 4 (dasabuvir) in specific weight ratios, combined with pharmaceutically acceptable stabilizing and release rate-modifying polymers, to enhance bioavailability and stability, allowing for a once-daily dosing regimen that is bioequivalent to existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard of care treatment with peginterferon-alpha and ribavirin is administered, then HCV infection can be treated, but side effects are significant and viral elimination is inadequate
Solution Approach 1:
The patent changes the chemical parameters of the treatment by introducing novel antiviral compounds (ABT-450, ABT-267, dasabuvir, and ritonavir) with optimized molecular structures. These compounds have improved pharmacokinetic properties and efficacy profiles compared to existing treatments, directly addressing the contradiction between viral elimination and side effects
Solution Approach 2:
The patent employs composite dosage forms containing multiple antiviral compounds in specific combinations. The fixed-dose combinations of ABT-450 plus ABT-267 plus dasabuvir, and ABT-450 plus ritonavir plus dasabuvir, create synergistic effects that enhance viral elimination while maintaining tolerability, resolving the contradiction between efficacy and side effects
2Reliability
If antiviral compounds with poor solubility are used, then new HCV treatment options can be developed, but bioavailability is limited
Solution Approach 1:
The patent optimizes the physicochemical parameters of the antiviral compounds through formulation science. By adjusting pH, using salt forms, and employing solubility-enhancing excipients, the patent improves the aqueous solubility and dissolution rate of compounds like ABT-450 and dasabuvir, thereby enhancing their bioavailability while maintaining treatment efficacy
Solution Approach 2:
The patent introduces pharmaceutical excipients and delivery systems as intermediaries between the poorly soluble antiviral compounds and the biological system. These intermediaries facilitate drug dissolution and absorption, bridging the gap between the hydrophobic drug molecules and the aqueous gastrointestinal environment, thus improving bioavailability
3Reliability
If antiviral compounds with high variability in pharmacokinetic profile are used, then new HCV treatment options can be developed, but dosing consistency is poor
Solution Approach 1:
The patent optimizes pharmacokinetic parameters through careful selection of compound derivatives and formulation strategies. By modifying molecular structure and formulation characteristics, the patent reduces inter- and intra-patient variability in absorption, distribution, metabolism, and excretion, achieving more consistent plasma concentration profiles and dosing responses
Solution Approach 2:
The patent incorporates pharmacokinetic feedback mechanisms through therapeutic drug monitoring and dose adjustment protocols. By measuring plasma concentrations and adjusting dosing regimens based on observed pharmacokinetic behavior, the patent compensates for variability and achieves consistent therapeutic outcomes across diverse patient populations
Data Source
AI summary
The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.